ReviewSeminars in respiratory and critical care medicine2016
Metapneumovirus Infections and Respiratory Complications.
Review in Seminars in respiratory and critical care medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 49 citations in OpenAlex.
- Human metapneumovirus infection in pregnancy: A systematic review of cohort studies and case reports.World journal of virology · 2026Article
- Comparison of human metapneumovirus and respiratory syncytial virus in children with acute lower respiratory infections in Wenzhou, China from 2021 to 2022: a retrospective study.BMC pediatrics · 2026Article
- Article
- Early-life viral infection generates pathological tissue-resident memory cells that contribute to asthma-like disease.JCI insight · 2026Article
- Clinical Outcomes and Molecular Epidemiology of Human Metapneumovirus in Romanian Hospitalized Patients.Microorganisms · 2026Article
- Forging a global shield against HMPV: Uniting healthcare systems and community action to counter a silent respiratory epidemic.AIMS public health · 2026Review
- Article
- Gut microbiota and serum metabolome in children with human metapneumovirus infection.Frontiers in immunology · 2026Article
- Advances in Human Metapneumovirus Research: Clinical Impact, Diagnostic Innovations, and Therapeutic Challenges.Pathogens (Basel, Switzerland) · 2025Review
- hMPV co-infections: Distinct immunopathogenic mechanisms and clinical implications of viral and bacterial pathogenesis.Folia microbiologica · 2025Review
- Severe Manifestations of Human Metapneumovirus With Co-infections: A Case Series and Literature Review.Cureus · 2025Article
- Human Metapneumovirus: A Narrative Review on Emerging Strategies for Prevention and Treatment.Viruses · 2025Review
- Incidence of Human Metapneumovirus Among Older Adults in 10 High-Income Countries: A Systematic Literature Review, Meta-analysis, and Modeling Study.Open forum infectious diseases · 2025Article
- hMPV Outbreaks: Worldwide Implications of a Re-Emerging Respiratory Pathogen.Microorganisms · 2025Review
- Human metapneumovirus (hMPV) in 2025: emerging trends and insights from community and hospital-based respiratory panel analyses-a comprehensive review.Virology journal · 2025Review
- Epidemiological and Clinical Characteristics of Human Metapneumovirus-Associated Acute Respiratory Tract Infection Cases in the Pudong New Area, Shanghai, from 2014 to 2023.Journal of epidemiology and global health · 2025Article
- Case Report: Unusual radiological findings in adult human metapneumovirus infection.Frontiers in medicine · 2025Article
- Probenecid Inhibits Human Metapneumovirus (HMPV) Replication In Vitro and in BALB/c Mice.Viruses · 2024Article
- Seasonal and Genetic Characteristics of Human Metapneumovirus Circulating - Henan Province, China, 2017-2023.China CDC weekly · 2024Article
- Exploring Clinical Predictors of Severe Human Metapneumovirus Respiratory Tract Infections in Children: Insights from a Recent Outbreak.Microorganisms · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute respiratory tract infections (ARTIs) are the most common illnesses experienced by people of all ages worldwide. In 2001, a new respiratory pathogen called human metapneumovirus (hMPV) was identified in respiratory secretions. hMPV is an RNA virus of the Paramyxoviridae family, and it has been isolated on every continent and from individuals of all ages. hMPV causes 7 to 19% of all cases of ARTIs in both hospitalized and outpatient children, and the rate of detection in adults is approximately 3%. Symptoms of hMPV infection range from a mild cold to a severe disease requiring a ventilator and cardiovascular support. The main risk factors for severe disease upon hMPV infection are the presence of a high viral load, coinfection with other agents (especially human respiratory syncytial virus), being between 0 and 5 months old or older than 65 years, and immunodeficiency. Currently, available treatments for hMPV infections are only supportive, and antiviral drugs are employed in cases of severe disease as a last resort. Ribavirin and immunoglobulins have been used in some patients, but the real efficacy of these treatments is unclear. At present, the direction of research on therapy for hMPV infection is toward the development of new approaches, and a variety of vaccination strategies are being explored and tested in animal models. However, further studies are required to define the best treatment and prevention strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.